Skip to main content

Table 2 Clinical results in the four groups

From: Use of marginal organs in kidney transplantation for marginal recipients: too close to the margins of safety?

  Group 1:
Donor and
recipient
non-marginal
Group 2:
Donor non-
marginal,
recipient
marginal
Group 3:
Donor
marginal,
recipient
non-marginal
Group 4:
Donor and
recipient
marginal
P -value
No. of patients 138 41 69 84 -
Duration of surgery (minutes) 159 ± 63 164 ± 63 153 ± 41 173 ± 71 0.358
Immunosuppression      
Mycophenolate mofetil (Cell Cept) 101 (73%) 24 (59%) 44 (64%) 53 (63%) 0.203
Tacrolimus 86 (62%) 22 (54%) 37 (54%) 49 (58%) 0.593
Cyclosporin A 44 (32%) 18 (44%) 25 (36%) 30 (36%) 0.559
Sirolimus 5 (4%) 1 (2%) 11 (16%) 4 (5%) 0.003
Intensive care stay donor (days) 6.2 ± 5.7 6.9 ± 6.6 6.1 ± 6.0 3.5 ± 3.2 0.001§
Hospital stay recipient (days) 18.0 ± 14.0 18.9 ± 14.2 15.7 ± 11.6 17.7 ± 19.5 0.699
Any complication * 48 (36%) 20 (49%) 36 (52%) 36 (43%) 0.151
Rejection 38 (28%) 2 (5%) 27 (39%) 26 (31%) 0.001
Primary non-function requiring dialysis 50 (38%) 11 (27%) 20 (29%) 32 (39%) 0.355
Loss of graft 8 (6%) 2 (5%) 7 (10%) 8 (10%) 0.539
Death 3 (2%) 2 (5%) 1 (1%) 6 (7%) 0.176
  1. * except urinary tract infection; § additional nonparametric testing yielded a P = 0.001 by Kruskal-Wallis test